ARGX - Argen X SE - ADR
IEX Last Trade
517.635
-0.025 -0.005%
Share volume: 166,053
Last Updated: Fri 30 Aug 2024 09:59:56 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$517.66
-0.03
-0.01%
Fundamental analysis
4%
Profitability
0%
Dept financing
0%
Liquidity
0%
Performance
10%
Performance
5 Days
0.12%
1 Month
1.59%
3 Months
42.84%
6 Months
30.08%
1 Year
2.78%
2 Year
35.76%
Key data
Stock price
$517.64
DAY RANGE
$513.53 - N/A
52 WEEK RANGE
$327.73 - $540.49
52 WEEK CHANGE
$0.00
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
10/31/2024
Company detail
CEO: Tim Van Hauwermeiren
Region: US
Website: https://www.argenx.com/
Employees: 336
IPO year: -
Issue type: American Depository Receipt (ADR’s)
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: https://www.argenx.com/
Employees: 336
IPO year: -
Issue type: American Depository Receipt (ADR’s)
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer.
Recent news